Research
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
Jasvinder A. Singh, Robin Christensen, George A. Wells, Maria E. Suarez-Almazor, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Elizabeth Tanjong Ghogomu and Peter Tugwell
CMAJ November 24, 2009 181 (11) 787-796; DOI: https://doi.org/10.1503/cmaj.091391
Jasvinder A. Singh
Robin Christensen
George A. Wells
Maria E. Suarez-Almazor
Rachelle Buchbinder
Maria Angeles Lopez-Olivo
Elizabeth Tanjong Ghogomu
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
Jasvinder A. Singh, Robin Christensen, George A. Wells, Maria E. Suarez-Almazor, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Elizabeth Tanjong Ghogomu, Peter Tugwell
CMAJ Nov 2009, 181 (11) 787-796; DOI: 10.1503/cmaj.091391
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
Jasvinder A. Singh, Robin Christensen, George A. Wells, Maria E. Suarez-Almazor, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Elizabeth Tanjong Ghogomu, Peter Tugwell
CMAJ Nov 2009, 181 (11) 787-796; DOI: 10.1503/cmaj.091391
Jump to section
Related Articles
Cited By...
- Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study
- Improving patient-centred care for rheumatoid arthritis
- Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy
- Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
- Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial
- Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial
- Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials
- Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons
- Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
- Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples
- Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings
- Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012
- Comparative effectiveness and safety of biological treatment options after tumour necrosis factor {alpha} inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis
- Drug therapy of inflammatory arthritis
- A mindfulness-based group intervention to reduce psychological distress and fatigue in patients with inflammatory rheumatic joint diseases: a randomised controlled trial
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
- Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0
- Smoking and Outcomes After Knee and Hip Arthroplasty: A Systematic Review
- The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
- Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis